Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 131, Issue 1-2, 2002, Pages 104-114

  Marracci, Gail H ^a,b   Jones, Richard E ^a,b,c   McKeon, Gabriel P ^b,c   Bourdette, Dennis N ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alpha lipoic acid; EAE; Matrix metalloproteinase; MMP inhibitor; Multiple sclerosis

Indexed keywords

ANTIOXIDANT; DIHYDROLIPOATE; ENZYME INHIBITOR; FREUND ADJUVANT; GELATINASE B; PROTEOLIPID PROTEIN; PROTEOLIPID PROTEIN[139-151]; THIOCTIC ACID; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TYPE; CONTROLLED STUDY; DEMYELINATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IMMUNIZATION; INFLAMMATION; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; MACROPHAGE; MIGRATION INHIBITION; MONOCYTE; MOUSE; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; TREATMENT OUTCOME;

ACUTE DISEASE; ANIMALS; ANTIOXIDANTS; CELL MOVEMENT; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; LYMPH NODES; MATRIX METALLOPROTEINASE 9; MICE; MYELIN PROTEOLIPID PROTEIN; PEPTIDE FRAGMENTS; RECURRENCE; SPINAL CORD; T-LYMPHOCYTES; THIOCTIC ACID;

EID: 0036790853     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00269-2     Document Type: Article

References (39)

1. Barnes P.J., Karin M. Nuclear factor-{kappa}B - a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336:1997;1066-1071.
2. Bauer J., Bradl M., Hickley W., Forss-Petter S., Breitschopf H., Linington C., Wekerle H., Lassmann H. T-cell apoptosis in inflammatory brain lesions: destruction of T cells does not depend on antigen recognition. Am. J. Pathol. 153:1998;715-724.
3. Bierhaus A., Chevion S., Chevion M., Hofmann M., Quehenberger P., Illmer T., Luther T., Berentshtein E., Tritschler H., Muller M., Wahl P., Ziegler R., Nawroth P. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes. 46:1997;1481-1490.
4. Biewenga G.P., Haenen G.R.M.M., Bast A. The pharmacology of the antioxidant lipoic acid. Gen. Pharmacol. 29:1997;315-331.
5. Bö L., Dawson T., Wesselingh S., Mork S., Choi S., Kong P., Hanley D., Trapp B. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 36:1994;778-786.
6. Bonetti B., Pohl J., Gao Y., Raine C. Cell death during autoimmune demyelination: effector but not target cells are eliminated by apoptosis. J. Immunol. 159:1997;5733-5741.
7. Bourdette D.N., Vandenbark A.A., Meshul C., Whitham R., Offner H. Basic protein-specific T-cell lines that induce experimental autoimmune encephalomyelitis in SJL/J mice: comparison with Lewis rat lines. Cell. Immunol. 112:1988;351-363.
8. Clements J.M., Cossins J.A., Wells G.M., Corkill D.J., Helfrich K., Wood L.M., Pigott R., Stabler G., Ward G.A., Gearing A.J., Miller K.M. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J. Neuroimmunol. 74:1997;85-94.
9. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., van den Oord J., Sciot R., Meinhardt T., Hammerling G., Opdenakker G., Arnold B. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 104:1999;1507-1515.
10. Gijbels K., Galardy R.E., Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J. Clin. Invest. 94:1994;2177-2182.
11. Handelman G.J., Han D., Tritschler H., Packer L. Alpha-lipoic acid reduction by mammalian cells to the dithiol form, and release into the culture medium. Biochem. Pharmacol. 47:1994;1725-1730.
12. Hashimoto N., Kawabe T., Hara T., Imaizumi K., Wakayama H., Saito H., Shimokata K., Hasegawa Y. Effect of erythromycin on matrix metalloproteinase-9 and cell migration. J. Lab. Clin. Med. 137:2001;176-183.
13. Hewson A.K., Smith T., Leonard J.P., Cuzner M.L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 44:1995;345-349.
14. Kleiner D.E., Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 218:1994;325-329.
15. Koprowski H., Zheng Y.M., Heber-Katz E., Fraser N., Rorke L., Fu Z.F., Hanlon C., Dietzschold B. In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Neurobiology. 90:1993;3024-3027.
16. Leppert D., Waubant E., Galardy R., Bunnett N.W., Hauser S.L. T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 154:1995;4379-4389.
17. Leppert D., Waubant E., Bürk M.R., Oksenberg J.R., Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:1996;846-852.
18. Liedtke W., Cannella B., Mazzaccaro R.J., Clements J.M., Miller K.M., Wucherpfennig K.W., Gearing A.J., Raine C.S. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 44:1998;35-46.
19. Lindberg R.L., De Groot C.J., Montagne L., Freitag P., van der Valk P., Kappos L., Leppert D. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain. 124:2001;1743-1753.
20. Merrill J., Murphy S. Inflammatory events at the blood brain barrier: regulation of adhesion molecules, cytokines, and chemokines by reactive nitrogen and oxygen species. Brain Behav. Immun. 11:1997;245-263.
21. Nagamatsu M., Nickander K., Schmelzer J., Raya A., Wittrock D., Tritschler H., Low P. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 18:1995;1160-1167.
22. Packer L., Witt E.H., Tritschler H.J. Alpha-lipoic acid as a biological antioxidant. Free Radic. Biol. Med. 19:1995;227-250.
23. Panigrahi M., Sadguna Y., Shivakumar B., Kolluri S., Roy S., Packer L., Ravindranath V. Alpha-lipoic acid protects against reperfusion injury following cerebral ischemia in rats. Brain Res. 717:1996;184-188.
24. Romanic A.M., Madri J.A. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol. 4:1994;145-156.
25. Schmied M., Breitschopf H., Gold R., Zischler H., Rothe G., Wekerle H., Lassmann H. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am. J. Pathol. 143:1993;446-452.
26. Springman E.B., Angleton E.L., Birkedal-Hansen H., Van Wart H.E. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc. Natl. Acad. Sci. U. S. A. 87:1990;364-368.
27. Stüve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., Yong V.W. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40:1996;853-863.
28. Stüve O., Chabot S., Jung S.S., Williams G., Yong V.W. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J. Neuroimmunol. 80:1997;38-46.
29. Suzuki Y.J., Aggarwal B.B., Packer L. Alpha-lipoic acid is a potent inhibitor of NF-kappa B activation in human T cells. Biochem. Biophys. Res. Commun. 189:1992;1709-1715.
30. Teichert J., Preiβ R. Determination of lipoic acid in human plasma by high-performance liquid chromatography with electrochemical detection. J. Chromatogr., B, Biomed. Sci. Appl. 672:1995;277-281.
31. Uhm J.H., Dooley N.P., Stüve O., Francis G.S., Duquette P., Antel J.P., Yong V.W. Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy. Ann. Neurol. 46:1999;319-324.
32. van der Goes A., Brouwer J., Hoekstra K., Roos D., van d.B.T., Dijkstra C. Reactive oxygen species are required for the phagocytosis of myelin by macrophages. J. Neuroimmunol. 92:1998;67-75.
33. Van Wart H.E., Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. U. S. A. 87:1990;5578-5582.
34. Whitham R., Bourdette D., Hashim G., Herndon R., Ilg R., Vandenbark A., Offner H. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 146:1991;101-107.
35. Winyard P.G., Blake D.R. Antioxidants, redox-regulated transcription factors, and inflammation. Sies H. Antioxidants in Disease Mechanisms and Therapy. Advances in Pharmacology. vol. 38:1997;403-421 Academic Press, San Diego.
36. Wolz P., Krieglstein J. Neuroprotective effects of alpha-lipoic acid and its enantiomers demonstrated in rodent models of focal cerebral ischemia. Neuropharmacology. 35:1996;369-375.
37. Yong V.W., Chabot S., Stüve O., Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 51:1998;682-689.
38. Ziegler D., Gries F. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 46(Suppl. 2):1997;S62-S66.
39. Ziegler D., Hanefeld M., Ruhnau K., Meissner H., Lobisch M., Schutte K., Gries F. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 38:1995;1425-1433.